Answers are grounded in this paper and cite their sources.
New insights into tumor-induced B-cell changes in blood and bone marrow of triple-negative breast cancer (TNBC) patients show two distinct patterns of B-cell abnormalities that could serve as biomarkers for determining the likelihood of response to standard-of-care chemotherapy (SoC) and immunotherapy.
No takes yet. Share an insight, caveat, or question.
Peter Hofland (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: